GEP20156233B - New combination between 4-{3-[cis-hexahydrocyclopenta [c]pyrol-2(1h)-yl]propoxy} benzamide and nmda receptor antagonist and pharmaceutcal compositions containing thereof - Google Patents
New combination between 4-{3-[cis-hexahydrocyclopenta [c]pyrol-2(1h)-yl]propoxy} benzamide and nmda receptor antagonist and pharmaceutcal compositions containing thereofInfo
- Publication number
- GEP20156233B GEP20156233B GEAP201212913A GEAP2012012913A GEP20156233B GE P20156233 B GEP20156233 B GE P20156233B GE AP201212913 A GEAP201212913 A GE AP201212913A GE AP2012012913 A GEAP2012012913 A GE AP2012012913A GE P20156233 B GEP20156233 B GE P20156233B
- Authority
- GE
- Georgia
- Prior art keywords
- hexahydrocyclopenta
- pyrol
- benzamide
- propoxy
- cis
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 title abstract 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There are represented combination containing 4-{3-[cis-hexahydrocyclopenta[C]pyrol-2(1H)- yl]propoxy}benzamide of formula (I) and antagonist of receptor NMDA. Said combination is applied at the treatment of cognitive disorders associated with cerebral aging and neurodegenerative diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568831P | 2011-12-09 | 2011-12-09 | |
| FR1103777A FR2983732B1 (en) | 2011-12-09 | 2011-12-09 | NOVEL ASSOCIATION BETWEEN 4- {3- [CIS-HEXAHYDROCYCLOPENTA [C] PYRROL-2 (1H) -YL] PROPOXY} PHARMACEUTICALS CONTAINING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20156233B true GEP20156233B (en) | 2015-01-26 |
Family
ID=47278205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201212913A GEP20156233B (en) | 2011-12-09 | 2012-12-07 | New combination between 4-{3-[cis-hexahydrocyclopenta [c]pyrol-2(1h)-yl]propoxy} benzamide and nmda receptor antagonist and pharmaceutcal compositions containing thereof |
Country Status (3)
| Country | Link |
|---|---|
| GE (1) | GEP20156233B (en) |
| RU (1) | RU2014127731A (en) |
| SV (1) | SV2012004361A (en) |
-
2012
- 2012-12-07 RU RU2014127731A patent/RU2014127731A/en not_active Application Discontinuation
- 2012-12-07 SV SV2012004361A patent/SV2012004361A/en not_active Application Discontinuation
- 2012-12-07 GE GEAP201212913A patent/GEP20156233B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014127731A (en) | 2016-01-27 |
| SV2012004361A (en) | 2015-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00335A (en) | ||
| IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EP2560660A4 (en) | Chemosensory receptor ligand-based therapies | |
| WO2013003586A8 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| EP2925775A4 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| MY171091A (en) | Inhibitors of b-secretase | |
| EP2827856A4 (en) | Compounds and compositions for the treatment of muscular disorders | |
| EP2938616A4 (en) | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. | |
| GEP20146076B (en) | New association between 4-{3-[cis-hexahydrocyclopenta[c] pyrrol-2(1h)-yl]propoxy}ben¬za¬mide and acetylcholinesteraze inhibitor, and pharmaceutical compositions containing thereof | |
| MD20150023A2 (en) | Novel bicyclic pyridinones | |
| IN2015DN00372A (en) | ||
| EP2782566A4 (en) | L-SERINE COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS | |
| MX2011012669A (en) | Novel glucocorticoid receptor agonists. | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| EP2882495A4 (en) | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders | |
| MX351631B (en) | Compositions and methods for reducing the incidence of equine digestive disorders. | |
| EP2847158A4 (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| TN2014000532A1 (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| MD4345B1 (en) | Synthesis process, and crystalline forms of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy]benzamide hydrochloride and of free base, pharmaceutical compositions containing them for the treatment of cognitive and psycho-behavioural disorders | |
| CL2012003437A1 (en) | Association comprising 4- {3- [cis-hexahydrocyclopenta [c] pyrrol-2 (1h) -yl] propoxy} benzamide and an nmda receptor antagonist; pharmaceutical composition; and use for the treatment of cognitive disorders associated with brain aging and neurodegenerative diseases such as Alzheimer's disease. | |
| IN2015DN01736A (en) | ||
| GEP20156233B (en) | New combination between 4-{3-[cis-hexahydrocyclopenta [c]pyrol-2(1h)-yl]propoxy} benzamide and nmda receptor antagonist and pharmaceutcal compositions containing thereof | |
| MX2015005312A (en) | 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists. |